Pacira Pharmaceuticals Given “Buy” Rating at Jefferies Group (PCRX)
Pacira Pharmaceuticals (NASDAQ:PCRX)‘s stock had its “buy” rating restated by analysts at Jefferies Group in a research report issued to clients and investors on Friday. They currently have a $109.00 target price on the stock, up from their previous target price of $86.00. Jefferies Group’s target price would indicate a potential upside of 13.62% from the stock’s previous close.
Several other analysts have also recently commented on the stock. Analysts at Brean Capital raised their price target on shares of Pacira Pharmaceuticals from $86.00 to $111.00 in a research note on Thursday. They now have a “buy” rating on the stock. Separately, analysts at Bank of America reiterated a “positive” rating on shares of Pacira Pharmaceuticals in a research note on Thursday, July 17th. Finally, analysts at Barclays raised their price target on shares of Pacira Pharmaceuticals from $85.00 to $107.00 in a research note on Wednesday, July 16th. They now have an “overweight” rating on the stock. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $104.68.
Shares of Pacira Pharmaceuticals (NASDAQ:PCRX) opened at 95.93 on Friday. Pacira Pharmaceuticals has a one year low of $34.11 and a one year high of $96.95. The stock’s 50-day moving average is $87.58 and its 200-day moving average is $75.41. The company’s market cap is $3.420 billion.
Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its quarterly earnings results on Thursday, July 31st. The company reported $0.04 earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.21) by $0.25. The company had revenue of $47.20 million for the quarter, compared to the consensus estimate of $42.20 million. Pacira Pharmaceuticals’s revenue was up 175.2% compared to the same quarter last year. Analysts expect that Pacira Pharmaceuticals will post $-0.44 EPS for the current fiscal year.
Pacira Pharmaceuticals, Inc is a United States-based pharmaceutical company. The Company develops non-opioid products for postsurgical pain control.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.